{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:55:55Z","timestamp":1790016955531,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00228-023-03616-y","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T05:02:05Z","timestamp":1704862925000},"page":"335-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-7516","authenticated-orcid":false,"given":"Kexin","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-7514","authenticated-orcid":false,"given":"Wenxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"3616_CR1","unstructured":"World Health Organization (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact.\u00a0https:\/\/apps.who.int\/iris\/handle\/10665\/341412. Accessed July\u00a07 2023"},{"key":"3616_CR2","doi-asserted-by":"publisher","unstructured":"Choi HSJ, Tonthat A, Janssen HLA et al (2022) Aiming for functional cure with established and novel therapies for chronic hepatitis B. hepatol Commun6(5):935\u2013949. https:\/\/doi.org\/10.1002\/hep4.1875","DOI":"10.1002\/hep4.1875"},{"key":"3616_CR3","doi-asserted-by":"publisher","unstructured":"Chinese Society of Hepatology CMA (2022) Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chinese J hepatol 30(12):1309\u20131331.\u00a0https:\/\/doi.org\/10.3760\/cma.j.cn501113-20221204-00607","DOI":"10.3760\/cma.j.cn501113-20221204-00607"},{"key":"3616_CR4","doi-asserted-by":"publisher","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur heart J 41(1):111\u2013188.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"3616_CR5","doi-asserted-by":"publisher","unstructured":"Mena \u00c1, Pedreira JD, Castro \u00c1 et al (2014) Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol 29(1):173\u2013178.\u00a0https:\/\/doi.org\/10.1111\/jgh.12432","DOI":"10.1111\/jgh.12432"},{"key":"3616_CR6","doi-asserted-by":"publisher","unstructured":"Wong GL, Chan HL, Yu Z et al (2014) Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther 39(8):883\u2013893. https:\/\/doi.org\/10.1111\/apt.12658","DOI":"10.1111\/apt.12658"},{"key":"3616_CR7","doi-asserted-by":"publisher","unstructured":"Wang CC, Tseng TC, Kao JH (2015) Hepatitis B virus infection and metabolic syndrome: fact or fiction? J Gastroenterol Hepatol 30(1):14\u201320.\u00a0https:\/\/doi.org\/10.1111\/jgh.12700","DOI":"10.1111\/jgh.12700"},{"key":"3616_CR8","doi-asserted-by":"publisher","unstructured":"Lam L, Fontaine H, Bourliere M et al (2021) Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res hepatol Gastroenterol 45(5):101713.\u00a0https:\/\/doi.org\/10.1016\/j.clinre.2021.101713","DOI":"10.1016\/j.clinre.2021.101713"},{"key":"3616_CR9","doi-asserted-by":"publisher","unstructured":"Bondini S, Kallman J, Wheeler A et al (2007) Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 27(5):607\u2013611. https:\/\/doi.org\/10.1111\/j.1478-3231.2007.01482.x","DOI":"10.1111\/j.1478-3231.2007.01482.x"},{"key":"3616_CR10","doi-asserted-by":"publisher","unstructured":"Mak LY, Hui RW, Fung J et al (2020) Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol 73(4):800\u2013806.\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2020.05.040","DOI":"10.1016\/j.jhep.2020.05.040"},{"key":"3616_CR11","doi-asserted-by":"publisher","unstructured":"Hui RWH, Seto WK, Cheung KS et al (2018) Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat 25(1):97\u2013104. https:\/\/doi.org\/10.1111\/jvh.12766","DOI":"10.1111\/jvh.12766"},{"key":"3616_CR12","doi-asserted-by":"publisher","unstructured":"Seto WK, Hui RWH, Mak LY et al (2018) Association between hepatic steatosis, measured by controlled\u00a0attenuation parameter, and fibrosis burden in chronic hepatitis B. Clin Gastroenterol Hepatol: Offic Clin Prac J Am Gastroenterol Assoc 16(4):575\u2013583.e572.\u00a0https:\/\/doi.org\/10.1016\/j.cgh.2017.09.044","DOI":"10.1016\/j.cgh.2017.09.044"},{"key":"3616_CR13","doi-asserted-by":"publisher","unstructured":"Buti M, Riveiro-Barciela M, Esteban R (2018) Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int 38(1):84\u201389.\u00a0https:\/\/doi.org\/10.1111\/liv.13641","DOI":"10.1111\/liv.13641"},{"key":"3616_CR14","doi-asserted-by":"publisher","unstructured":"Chan L, Asriel B, Eaton EF et al (2018) Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. Curr Opin Nephrol Hypertens 27(2):102\u2013112.\u00a0https:\/\/doi.org\/10.1097\/mnh.0000000000000392","DOI":"10.1097\/mnh.0000000000000392"},{"key":"3616_CR15","doi-asserted-by":"publisher","unstructured":"Suzuki S, Nishijima T, Kawasaki Y et al (2017) Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-na\u00efve Asian patients: results from 12-year observational cohort. AIDS patient care and STDs 31(3):105\u2013112.\u00a0https:\/\/doi.org\/10.1089\/apc.2016.0286","DOI":"10.1089\/apc.2016.0286"},{"key":"3616_CR16","doi-asserted-by":"publisher","unstructured":"Agarwal K, Brunetto M, Seto WK et al (2018) 96\u202fweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672\u2013681. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"3616_CR17","doi-asserted-by":"publisher","unstructured":"Buti M, Gane E, Seto WK et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):196\u2013206. https:\/\/doi.org\/10.1016\/s2468-1253(16)30107-8","DOI":"10.1016\/s2468-1253(16)30107-8"},{"key":"3616_CR18","doi-asserted-by":"publisher","unstructured":"EASL (2017) Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"3616_CR19","doi-asserted-by":"publisher","unstructured":"Suzuki K, Suda G, Yamamoto Y et al (2022) Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PloS One 17(1):e0261760.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0261760","DOI":"10.1371\/journal.pone.0261760"},{"key":"3616_CR20","doi-asserted-by":"publisher","unstructured":"Byun KS, Choi J, Kim JH et al (2022) Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol hepatol: Offic Clin Prac J Am Gastroenterol Assoc 20(2):427\u2013437.e425.\u00a0https:\/\/doi.org\/10.1016\/j.cgh.2021.04.045","DOI":"10.1016\/j.cgh.2021.04.045"},{"key":"3616_CR21","doi-asserted-by":"publisher","unstructured":"Jeong J, Shin JW, Jung SW et al (2022) Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin Mol Hepatol 28(2):254\u2013264.\u00a0https:\/\/doi.org\/10.3350\/cmh.2021.0314","DOI":"10.3350\/cmh.2021.0314"},{"key":"3616_CR22","doi-asserted-by":"publisher","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S et al (2017) Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther 46(6):599\u2013604.\u00a0https:\/\/doi.org\/10.1111\/apt.14218","DOI":"10.1111\/apt.14218"},{"key":"3616_CR23","doi-asserted-by":"publisher","unstructured":"Janicko M, Senajov\u00e1 G, Drazilov\u00e1 S et al (2014) Association between metabolic syndrome and hepatitis B virus infection in the Roma population in eastern Slovakia: a population-based study. Central Eur J Public Health 22Suppl:S37\u201342.\u00a0https:\/\/doi.org\/10.21101\/cejph.a3900","DOI":"10.21101\/cejph.a3900"},{"key":"3616_CR24","doi-asserted-by":"publisher","unstructured":"Razi B, Alizadeh S, Omidkhoda A et al (2017) Association of chronic hepatitis B infection with metabolic syndrome and its components: meta-analysis of observational studies. Diabetes Metab Syndr 11Suppl 2:S939-s947.\u00a0https:\/\/doi.org\/10.1016\/j.dsx.2017.07.020","DOI":"10.1016\/j.dsx.2017.07.020"},{"key":"3616_CR25","doi-asserted-by":"publisher","unstructured":"Donegan S, Williamson P, D'Alessandro U et al (2013) Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods 4(4):291\u2013323.\u00a0https:\/\/doi.org\/10.1002\/jrsm.1085","DOI":"10.1002\/jrsm.1085"},{"key":"3616_CR26","doi-asserted-by":"publisher","unstructured":"Bucher HC, Guyatt GH, Griffith LE et al (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683\u2013691.\u00a0https:\/\/doi.org\/10.1016\/s0895-4356(97)00049-8","DOI":"10.1016\/s0895-4356(97)00049-8"},{"key":"3616_CR27","doi-asserted-by":"publisher","unstructured":"Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21(16):2313\u20132324.\u00a0https:\/\/doi.org\/10.1002\/sim.1201","DOI":"10.1002\/sim.1201"},{"key":"3616_CR28","doi-asserted-by":"publisher","unstructured":"Terrault NA, Bzowej NH, Chang KM et al (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1):261\u2013283.\u00a0https:\/\/doi.org\/10.1002\/hep.28156","DOI":"10.1002\/hep.28156"},{"key":"3616_CR29","unstructured":"GA Wells BS, D O'Connell (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses.\u00a0https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 22 july 2021"},{"key":"3616_CR30","doi-asserted-by":"publisher","unstructured":"Shamsrizi P, Gladstone BP, Carrara E et al (2020) Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. BMJ open 10(1):e030266.\u00a0https:\/\/doi.org\/10.1136\/bmjopen-2019-030266","DOI":"10.1136\/bmjopen-2019-030266"},{"key":"3616_CR31","doi-asserted-by":"publisher","unstructured":"Salanti G, Del Giovane C, Chaimani A et al (2014) Evaluating the quality of evidence from a network meta-analysis. PloS one. 9(7):e99682.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0099682","DOI":"10.1371\/journal.pone.0099682"},{"key":"3616_CR32","doi-asserted-by":"publisher","unstructured":"Cipriani A, Higgins JP, Geddes JR et al (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159(2):130\u2013137.\u00a0https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","DOI":"10.7326\/0003-4819-159-2-201307160-00008"},{"key":"3616_CR33","doi-asserted-by":"publisher","unstructured":"Reken S, Sturtz S, Kiefer C et al (2016) Assumptions of mixed treatment comparisons in health technology assessments - challenges and possible steps for practical application. PloS One 11(8):e0160712.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0160712","DOI":"10.1371\/journal.pone.0160712"},{"key":"3616_CR34","doi-asserted-by":"publisher","unstructured":"Tonin FS, Rotta I, Mendes AM et al (2017) Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Prac 15(1):943.\u00a0https:\/\/doi.org\/10.18549\/PharmPract.2017.01.943","DOI":"10.18549\/PharmPract.2017.01.943"},{"key":"3616_CR35","doi-asserted-by":"publisher","unstructured":"Higgins JP, Jackson D, Barrett JK et al (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98\u2013110.\u00a0https:\/\/doi.org\/10.1002\/jrsm.1044","DOI":"10.1002\/jrsm.1044"},{"key":"3616_CR36","doi-asserted-by":"publisher","unstructured":"van Valkenhoef G, Dias S, Ades AE et al (2016) Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods 7(1):80\u201393.\u00a0https:\/\/doi.org\/10.1002\/jrsm.1167","DOI":"10.1002\/jrsm.1167"},{"key":"3616_CR37","doi-asserted-by":"publisher","unstructured":"Salanti G, Kavvoura FK, Ioannidis JP (2008) Exploring the geometry of treatment networks. Ann Intern Med148(7):544\u2013553.\u00a0https:\/\/doi.org\/10.7326\/0003-4819-148-7-200804010-00011","DOI":"10.7326\/0003-4819-148-7-200804010-00011"},{"key":"3616_CR38","doi-asserted-by":"publisher","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163\u2013171.\u00a0https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"issue":"03","key":"3616_CR39","first-page":"384","volume":"34","author":"chen liwen GW","year":"2021","unstructured":"chen liwen GW (2021) Zhu Da, Study on the effecacy and safety of conversion from TDF to TAF in the treatment of CHB after virological response. Journal of Mathematical Medicine 34(03):384\u2013387","journal-title":"Journal of Mathematical Medicine"},{"key":"3616_CR40","doi-asserted-by":"publisher","unstructured":"Suzuki K, Suda G, Yamamoto Y et al (2021) Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol 56(2):168\u2013180.\u00a0https:\/\/doi.org\/10.1007\/s00535-020-01750-3","DOI":"10.1007\/s00535-020-01750-3"},{"key":"3616_CR41","doi-asserted-by":"publisher","unstructured":"Akdemir Kalkan I, Karasahin O, Sarigul F et al (2022) Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic hepatitis B initially treated with tenofovir disoproxil: a retrospective observational survey. Hepatitis Monthly 21(10).\u00a0https:\/\/doi.org\/10.5812\/hepatmon.118721","DOI":"10.5812\/hepatmon.118721"},{"key":"3616_CR42","doi-asserted-by":"publisher","unstructured":"Lim J, Choi WM, Shim JH et al (2022) Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na\u00efve chronic hepatitis B. Liver Int 42(7):1517\u20131527. https:\/\/doi.org\/10.1111\/liv.15261","DOI":"10.1111\/liv.15261"},{"key":"3616_CR43","doi-asserted-by":"publisher","unstructured":"Zhang Q, Liang J, Yin J et al (2022) Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients. J Med Virol 94(11):5465\u20135474.\u00a0https:\/\/doi.org\/10.1002\/jmv.27977","DOI":"10.1002\/jmv.27977"},{"key":"3616_CR44","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1002\/hep.32479","volume":"76","author":"Y Deng","year":"2022","unstructured":"Deng Y, Zhu L, Jiang XP et al (2022) The effect of nucleos(t)ide analogues on lipid profiles in patients with naive-treatment chronic hepatitis B. Hepatology 76:S266\u2013S267","journal-title":"Hepatology"},{"key":"3616_CR45","doi-asserted-by":"publisher","unstructured":"Li J, Hu C, Chen Y et al (2021) Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis 21(1):567.\u00a0https:\/\/doi.org\/10.1186\/s12879-021-06237-x","DOI":"10.1186\/s12879-021-06237-x"},{"key":"3616_CR46","unstructured":"Fehmi Tabak BM, Bahadir Ceylan, Alper Gunduz, Ozlem Aydin, Hayat Kumbasar, Aahant Cagatay, Levent Erdem, Funda Kocak, Resat Ozaras (2017) The effect of tenofovir and entecavir on lipid profile in chronic hepatitis B patients. In: Fehmi Tabak BM, Bahadir Ceylan, Alper Gunduz, Ozlem Aydin, Hayat Kumbasar, Aahant Cagatay, Levent Erdem, Funda Kocak, Resat Ozaras, editor. APASL;  Shanghai, China: Hepatol Int"},{"key":"3616_CR47","doi-asserted-by":"publisher","unstructured":"Kanda N, Okamoto K, Okumura H et al (2021) Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. HIV Med 22(6):457\u2013466.\u00a0https:\/\/doi.org\/10.1111\/hiv.13061","DOI":"10.1111\/hiv.13061"},{"key":"3616_CR48","doi-asserted-by":"publisher","unstructured":"Mallon PWG, Brunet L, Fusco JS et al (2022) Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open forum Infect Dis 9(1):ofab621.\u00a0https:\/\/doi.org\/10.1093\/ofid\/ofab621","DOI":"10.1093\/ofid\/ofab621"},{"key":"3616_CR49","doi-asserted-by":"publisher","unstructured":"Squillace N, Ricci E, Menzaghi B et al (2020) The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile. Drug design Dev Ther 14:5515\u20135520.\u00a0https:\/\/doi.org\/10.2147\/dddt.S274307","DOI":"10.2147\/dddt.S274307"},{"key":"3616_CR50","doi-asserted-by":"publisher","unstructured":"Milinkovic A, Berger F, Arenas-Pinto A et al (2019) Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS (London, England). 33(15):2387\u20132391.\u00a0https:\/\/doi.org\/10.1097\/qad.0000000000002350","DOI":"10.1097\/qad.0000000000002350"},{"key":"3616_CR51","doi-asserted-by":"publisher","unstructured":"Ogawa E, Nakamuta M, Koyanagi T et al (2022) Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther 56(4):713\u2013722.\u00a0https:\/\/doi.org\/10.1111\/apt.17107","DOI":"10.1111\/apt.17107"},{"key":"3616_CR52","doi-asserted-by":"publisher","unstructured":"Wong GLH, Gane E, Pan C et al (2021) Efficacy and safety of tenofovir alafenamide (Taf) vs tenofovir disoproxil fumarate (Tdf) in East Asian chronic hepatitis B patients following 5-years of treatment. Gut 70:A76-A76. https:\/\/doi.org\/10.1136\/gutjnl-2021-IDDF.79","DOI":"10.1136\/gutjnl-2021-IDDF.79"},{"key":"3616_CR53","doi-asserted-by":"publisher","unstructured":"Murakami E, Wang T, Park Y et al (2015) Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob agents Chemother 59(6):3563\u20133569.\u00a0https:\/\/doi.org\/10.1128\/aac.00128-15","DOI":"10.1128\/aac.00128-15"},{"key":"3616_CR54","doi-asserted-by":"publisher","unstructured":"Quispe R, Elshazly MB, Zhao D et al (2020) Total cholesterol\/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. Eur J Prev Cardiol 27(15):1597\u20131605.\u00a0https:\/\/doi.org\/10.1177\/2047487319862401","DOI":"10.1177\/2047487319862401"},{"key":"3616_CR55","doi-asserted-by":"publisher","unstructured":"Ingelsson E, Schaefer EJ, Contois JH et al (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. Jama 298(7):776\u2013785.\u00a0https:\/\/doi.org\/10.1001\/jama.298.7.776","DOI":"10.1001\/jama.298.7.776"},{"key":"3616_CR56","unstructured":"Fung SK, Ahn SH, Chen CY et al (2021) Atherosclerotic cardiovascular disease (Ascvd) risk profile of tenofovir alafenamide (Taf) versus tenofovir disoproxil fumarate (Tdf) in chronic Hbv (Chb) patients under antiviral therapy for 2 years. In: Fung SK, Ahn SH, Chen CY et al., editors. AASLD annual meeting; Oct, 2021: Hepatology 470A-471A"},{"key":"3616_CR57","doi-asserted-by":"publisher","unstructured":"Liu J, Zhao D, Hao YC et al (2022) [Low-density lipoprotein cholesterol levels and lipid-lowering treatment status among young and middle-aged ultra-high-risk patients with acute coronary syndrome in China]. Zhonghua xin xue guan bing za zhi 50(12):1161\u20131168.\u00a0https:\/\/doi.org\/10.3760\/cma.j.cn112148-20220920-00731","DOI":"10.3760\/cma.j.cn112148-20220920-00731"},{"key":"3616_CR58","doi-asserted-by":"publisher","unstructured":"Jankowski J, Floege J, Fliser D et al (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143(11):1157\u20131172. https:\/\/doi.org\/10.1161\/circulationaha.120.050686","DOI":"10.1161\/circulationaha.120.050686"},{"key":"3616_CR59","doi-asserted-by":"publisher","unstructured":"Li M, Zhou L, Dorsey HG et al (2020) Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line. Antiviral Res183:104948.\u00a0https:\/\/doi.org\/10.1016\/j.antiviral.2020.104948","DOI":"10.1016\/j.antiviral.2020.104948"},{"key":"3616_CR60","first-page":"S291","volume":"76","author":"YQ Duan","year":"2022","unstructured":"Duan YQ, Chen ZW, Hu P (2022) Impact of long-term tenofovir disoproxil fumarate treatment on hepatic lipid metabolism in mouse. Hepatology 76:S291\u2013S292","journal-title":"Hepatology"},{"key":"3616_CR61","doi-asserted-by":"publisher","unstructured":"Garbacz WG, Lu P, Miller TM et al (2016) Hepatic overexpression of CD36 improves glycogen homeostasis and attenuates high-fat diet-induced hepatic steatosis and insulin resistance. Mol Cell biol 36(21):2715\u20132727.\u00a0https:\/\/doi.org\/10.1128\/mcb.00138-16","DOI":"10.1128\/mcb.00138-16"},{"key":"3616_CR62","doi-asserted-by":"publisher","unstructured":"Pawlak M, Lefebvre P, Staels B (2015) Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62(3):720\u2013733.\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039","DOI":"10.1016\/j.jhep.2014.10.039"},{"key":"3616_CR63","doi-asserted-by":"publisher","unstructured":"Katsiki N, Kolovou G, Perez-Martinez P et al (2018) Dyslipidaemia in the elderly: to treat or not to treat?. Expert Rev Clin Pharmacol 11(3):259\u2013278.\u00a0https:\/\/doi.org\/10.1080\/17512433.2018.1425138","DOI":"10.1080\/17512433.2018.1425138"},{"key":"3616_CR64","doi-asserted-by":"publisher","unstructured":"Jo MJ, Lee JK, Kim JE et al (2023) Molecular mechanisms associated with aging kidneys and future perspectives. Int J Mol Sci 24(23).\u00a0https:\/\/doi.org\/10.3390\/ijms242316912","DOI":"10.3390\/ijms242316912"},{"key":"3616_CR65","doi-asserted-by":"publisher","unstructured":"Angelov A, Connelly PJ, Delles C et al (2023) Sex-biased and sex hormone-dependent regulation of apolipoprotein A1. Curr Opi Physiol 33:100654.\u00a0https:\/\/doi.org\/10.1016\/j.cophys.2023.100654","DOI":"10.1016\/j.cophys.2023.100654"},{"key":"3616_CR66","doi-asserted-by":"publisher","unstructured":"Pellegrini M, Pallottini V, Marin R et al (2014) Role of the sex hormone estrogen in the prevention of lipid disorder. Curr Med Chem 21(24):2734\u20132742.\u00a0https:\/\/doi.org\/10.2174\/0929867321666140303123602","DOI":"10.2174\/0929867321666140303123602"},{"key":"3616_CR67","doi-asserted-by":"publisher","unstructured":"Williams CM (2004) Lipid metabolism in women. Proc Nutr Soc 63(1):153\u2013160.\u00a0https:\/\/doi.org\/10.1079\/pns2003314","DOI":"10.1079\/pns2003314"},{"key":"3616_CR68","doi-asserted-by":"publisher","unstructured":"Morrone D, Weintraub WS, Toth PP et al (2012) Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atheroscl223(2):251\u2013261.\u00a0https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.02.016","DOI":"10.1016\/j.atherosclerosis.2012.02.016"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03616-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T09:06:46Z","timestamp":1708074406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03616-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3616"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03616-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"10 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}